



# COVID-19 Related Multi-System Inflammatory Syndrome in Children (MIS-C): A Systematic Review

Sharareh Kamfar<sup>1</sup>, Vahide Zeinali <sup>2,\*</sup>, Fariba Alaei <sup>3</sup>, Nazanin Farahbakhsh <sup>4</sup>, Shahrzad Tabatabaee<sup>5</sup>, Asieh Mosallanejad <sup>2,\*\*</sup>

<sup>1</sup> Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran

<sup>2</sup> Shahid Beheshti University of Medical Sciences, Tehran, Iran

<sup>3</sup> Pediatric Cardiology Department, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

<sup>4</sup> Pediatric Pulmonology Department, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

<sup>5</sup> Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

\* Corresponding Author: Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Email: vahide.zeynaly4183@gmail.com

\*\* Corresponding Author: Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Email: mosalladr@gmail.com

Received 2023 October 16; Revised 2024 May 25; Accepted 2024 May 29.

## Abstract

**Context:** Multisystem inflammatory syndrome in children (MIS-C) is a severe condition associated with SARS-CoV-2. The underlying reasons why some children develop MIS-C remain unclear.

**Objectives:** To review and summarize the existing evidence about the epidemiological and clinical characteristics, laboratory findings, therapeutic management, and outcomes of patients with COVID-19-related MIS-C.

**Methods:** This systematic review followed PRISMA guidelines. We searched PubMed and Google Scholar for studies on COVID-19 and MIS-C. Out of the 2026 research articles generated from our initial search on PubMed and Google Scholar on 20 December 2022, 44 met the inclusion criteria and were included in the review. Data on demographics, clinical features, laboratory findings, treatment, and outcomes were extracted.

**Results:** The median age of 7297 MIS-C patients was 8.6 years, with 59.2% being male. The most common symptoms were fever (98.7%), rash (55.2%), and conjunctivitis (52.8%). Obesity (27.1%) was the most prevalent comorbidity. Fifty percent of patients were admitted to pediatric intensive care; 631 received inotropes, and 374 required mechanical ventilation. Over 80% received IV immunoglobulin, and 77% received corticosteroids. Abnormal echocardiograms occurred in 77.5% of cases, with coronary artery aneurysms present in 18.5%. Most patients recovered, with a reported mortality rate of 1.7%.

**Conclusion:** Despite the limitations, our systematic review provides valuable insights into the characteristics and management of MIS-C based on existing global literature. While a large number of patients required intensive care and various therapeutic interventions, favorable short-term outcomes were demonstrated in the majority of patients, with notably low mortality rates.

**Keywords:** Multi-System Inflammatory Syndrome in Children, MIS-C, COVID-19, SARS-CoV-2, Systematic Review

## 1. Context

Multi-system inflammatory syndrome in children (MIS-C) is a seemingly rare but severe condition that has emerged as a significant concern associated with the COVID-19 pandemic (1). This novel clinical syndrome first emerged in April 2020 as a post-COVID-19 multisystem disorder. Since its emergence, the medical community has faced a new, concerning phenomenon (2). Multi-system inflammatory syndrome in children is

characterized by widespread inflammation affecting multiple organ systems in children and adolescents (3). The disease arises as a post-infectious immune dysregulation primarily associated with prior SARS-CoV-2 infection in children. The pathophysiological cascade involves an exaggerated immune response, notably the overactivation of T cells and macrophages. These immune cells contribute to a systemic inflammatory state impacting various organs. Studies by Dufort et al. (4) and Consiglio et al. (5) delve into the molecular

mechanisms. Dufort's research emphasizes the dysregulation of inflammatory cytokines, especially interleukin-6 (IL-6), while Consiglio's work highlights the viral spike protein's role in eliciting immune responses. These findings underscore the intricate interplay between immune cells and specific viral components in the manifestation of MIS-C.

Due to its rapid and severe clinical manifestation in pediatric populations, MIS-C has garnered significant attention, making prompt recognition and treatment imperative for managing this condition (6). Despite the Centers for Disease Control and Prevention (7) continuously tracking and collecting data, and providing updated guidance on this novel disease as new information emerges, the accurate incidence of MIS-C remains challenging due to a lack of comprehensive SARS-CoV-2 testing data (8). As researchers and healthcare professionals strive to unravel the complexities of this syndrome, a robust and evidence-based understanding is imperative to guide effective management and potential preventive strategies. The precise mechanisms leading to MIS-C remain enigmatic due to the numerous clinical presentations and the spectrum of severity in affected children, and are the subject of ongoing research (9). There are numerous uncertainties surrounding MIS-C that still need definitive answers. Considering the scarcity of available information on MIS-C and the evolving nature of knowledge in this area, a comprehensive and up-to-date review of the existing literature is essential to consolidate our current understanding, identify knowledge gaps, and propose avenues for future research.

## 2. Objectives

We aim to provide an in-depth review of the latest literature on MIS-C to clarify the clinical spectrum, diagnostic criteria, treatment modalities, and management strategies of this novel syndrome.

## 3. Methods

### 3.1. Data Sources

This systematic review was performed based on PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines to enhance the validity and transparency of the study (10). We searched

the PubMed and Google Scholar databases on December 20, 2022, with no regional or date of publication restrictions. The search terms used were: "Pediatric multisystem inflammatory disease," "Multisystem inflammatory syndrome in children," MIS-C, and MIS-C. The search was repeated on December 25, 2022, to ensure accuracy. The reference lists of all included studies were also searched to identify additional relevant studies.


### 3.2. Study Selection

Eligibility for inclusion in the study included cross-sectional and cohort studies focused on COVID-19-related MIS-C. Two reviewers independently assessed research titles to exclude studies that did not meet our inclusion criteria before conducting a full review of abstracts and full texts of selected studies. During full-text reviews, studies with insufficient data and those with sample sizes <10 patients were excluded.

To evaluate the methodological quality of the included studies, we employed the Newcastle-Ottawa Scale (NOS), a widely accepted tool for assessing the quality of non-randomized studies (11). Two independent reviewers appraised each study based on the NOS criteria, which evaluate the selection of study groups, comparability, and ascertainment of exposure or outcome. Any discrepancies in quality ratings were resolved through discussion until consensus was reached. The NOS scores, ranging from 0 to 9 stars, were recorded for each study and used to explore potential sources of heterogeneity in subgroup analyses. Studies with NOS scores  $\geq 7$  were considered high quality, while those with scores <5 were deemed low quality and subjected to sensitivity analyses to assess their impact on the overall findings.

### 3.3. Data Extraction

Two independent authors conducted the data extraction process for each article. The information extracted included bibliographic data (title, author/s, publication year), demographic data (age, gender, geographic area, race/ethnicity, comorbidities), clinical data (manifestations and diagnostic information), laboratory data (inflammatory markers, hematology, and cardiac markers), therapeutic management and outcomes data (immunomodulator agents, antibiotics, antiviral medications, and other treatment regimens,



**Figure 1.** PRISMA flow diagram of study inclusions and exclusions

hospitalization, admission to pediatric intensive care, mortality). Due to significant variations in data reporting among the included studies, meta-analysis and statistical calculations were not performed.

## 4. Results

### 4.1. Study Characteristics

For MIS-C, the search strategy yielded 2026 potentially relevant articles. Four hundred eighty-nine articles were identified as duplicates, and 28 non-English articles were removed. After initial screening of titles and abstracts, 1300 articles were excluded due to

study design and irrelevance to COVID-19. Reviewers retrieved and screened the full texts of 200 articles. During full-text screening, 156 articles were further excluded primarily due to absence of quantitative data and inadequate sample size. Additionally, studies with duplicated data from updated sources and those with mixed data of patients with COVID-19 and MIS-C were excluded at this stage.

To meet inclusion criteria, the majority of articles required confirmation of MIS-C that aligned with criteria set forth by the CDC (7). Ultimately, 44 studies (4, 12-54) met inclusion criteria for data extraction (Figure 1). These included 30 retrospective, seven prospective,

**Table 1.** Bibliographic and Demographic data of Articles Identified in the Systematic Review <sup>a</sup>

Study No	First Author (Publication Year)	Number of Patients/Males	Age (y)	Race/Ethnicity
1	Abdel-Haq et al. (2021) (12)	33/15	6.0 (3.0 - 9.0)	African American (75.8%), Middle Eastern (6.1%), Caucasian (9.1%), other (3%)
2	Alkan et al. (2021) (13)	36/19	7.8 (1.4 - 17)	NR
3	Başar et al. (2021) (14)	24/14	9.2 (0.8 - 15)	NR
4	Belhadjer et al. (2020) (15)	35/18	10 (2 - 16)	NR
5	Blumfield et al. (2021)	16/10	10 (1.6 - 20)	NR
6	Capone et al. (2020) (16)	33/20	8.6 (5.5 - 12.6)	Hispanic (27%), non-Hispanic (73%), white non-Hispanic (37%), black non-Hispanic (21%), Asian (15%), and other (24%).
7	Carter et al. (2020) (18)	25/15	12.5 (7.7 - 14.4)	Asian (20%), black (36%), white (40%), other (4%)
8	Miller et al. (2019) (19)	44/20	11 (0.6 - 20)	White, non-Hispanic (20.5%), black/African American (20.5), Hispanic (34%), not reported/declined to answer (25%)
9	Whittaker et al. (2020) (20)	58/38	9 (5.7 - 14)	Black (38%), Asian (31%), white (21%), other (10%)
10	Davies et al. (2020) (21)	78/52	11 (8 - 14)	Afro-Caribbean (47%), Asian (28%), white (22%), other (3%)
11	Dufort et al. (2020) (4)	99/53	< 21	Hispanic (36%), non-Hispanic (64%)
12	Dionne et al. (2020) (22)	25/15	9.7 (2.7 - 15.0)	NR
13	Pouletty et al. (2020) (23)	268/161	8.21 (4.03 - 12.09)	White (42.5%), black/African/ Caribbean/ black British (22.4%), Asian/ Asian British (23.5%), Mixed/ multiple ethnic groups (4.1%), other ethnic groups (3.7%)
14	Hameed et al. (2021) (24)	35/27	11 (6 - 14)	NR
15	Dhanalakshmi et al. (2020) (25)	19/8	6 (1.1 - 16)	NR
16	de Farias et al. (2020) (26)	11/9	4.9 (0.6 - 11)	NR
17	Moraleda et al. (2021) (27)	31/18	7.6 (4.5 - 11.5)	NR
18	Feldstein et al. (2020) (28)	186/115	8.3 (3.3 - 12.5)	White, non-Hispanic (19%), black, non-Hispanic (25%), Hispanic or Latino (31%), another race, non-Hispanic (5%)
19	Toubiana et al. (2020) (29)	21/9	7.9 (3.7 - 16.6)	NR
20	Sozeri et al. (2021) (30)	67/48	1 - 18	NR
21	Haslak et al. (2021) (31)	76/22	8.17 ± 4.42	NR
22	Bowen et al. (2021) (32)	2818/1664	< 20	Hispanic/Latino (37%), non-Hispanic black (28.8%), non-Hispanic white (27.7%)
23	Al-Harbi et al. (2021) (33)	54/30	3.4	Arab (75.9%), black or African (7.4%), South Asian (3.7%), Southeast Asian (5.6%), West Asian (7.4%)
24	Feldstein et al. (2021) (34)	539/312	8.9 (4.7 - 13.2)	White, non-Hispanic (13.3%), black, non-Hispanic (34.7%), Hispanic or Latino (35.9%), other, non-Hispanic (5.5%)
25	Abrams et al. (2021) (35)	1080/602	8 (4 - 12)	NR
26	Acevedo et al. (2021) (36)	78/46	7 (1 - 11)	NR
27	Valverde et al. (2021) (37)	286/194	8.4 (3.8 - 12.4)	White (56.3%), black (20.6%), Asian (10.1%), Mixed (5.9%), other (7.1%)
28	Deep et al. (2020) (38)	116/76	11 (7 - 14)	Afro-Caribbean (45%), Asian (26%), Caucasian (39%), other (11%)
29	Tripathi et al. (2021) (39)	171/103	8.7 (5.0 - 13)	Hispanic (27.3%)
30	Suresh Kumar et al. (2021) (40)	40/26	7 (5 - 10)	NR
31	Martin et al. (2021) (41)	439/259	9 (1 - 18)	Hispanic (5.69%), non-Hispanic (15.25%), white (9.33%), black (7.51%)
32	Verdugo et al. (2021) (42)	32/18	6.8 ± 3.9	NR
33	Kaushik et al. (2020) (43)	33/20	10 (6 - 13)	Hispanic or Latino (45%), black (39%), white (9%), Asian (3%), other (3%)
34	Lee et al. (2020) (44)	28/16	9 (1 - 17)	White (36%), black (18%), Hispanic (43%)
35	Lima-Setta et al. (2021) (45)	56/39	6.2 (2.4 - 10.3)	White (41%), mixed race/ethnicity (39%), black (18%), Asian (2%)
36	Mamishi et al. (2020) (46)	45/24	7 (10 - 17)	NR
37	Nino-Taravilla et al. (2021) (47)	26/15	6.5 (2 - 10.5)	NR
38	Patnaik et al. (2021) (48)	21/13	8.5 (2 - 16)	NR
39	Penner et al. (2021) (49)	46/30	10.2 (8.8 - 13.3)	African-Caribbean (35%), South Asian (24%), other (22%)
40	Ramcharan et al. (2020) (50)	15/11	8.8 (6.4 - 11.2)	African/Afro-Caribbean (40%), South Asian (40%), Mixed (13%), other (7%)
41	Roberts et al. (2022) (51)	50/33	9.65 (6.22 - 14.0)	White (30%), black (18%), other (24%), Missing/declined to answer (28%)
42	Swann et al. (2020) (52)	52/31	4.6 (0.3 - 13.7)	White (57%), South Asian (12%), black (10%)
43	Torres et al. (2020) (53)	27/14	6 (0 - 14)	NR
44	Rosanova et al. (2021) (54)	25/9	8.6 (5.1 - 10.5)	NR

<sup>z</sup> Abbreviation: NR, not reported.

<sup>a</sup> Values are expressed as median (minimum-maximum) or mean ± standard deviation.

four cohort, and three cross-sectional studies; all were observational.

Using the NOS to assess study quality, all 44 studies included in this systematic review achieved high-quality

ratings, indicating robust methodological rigor in their design and conduct.

#### 4.2. Epidemiological and Clinical Characteristics of Multi-System Inflammatory Syndrome in Children Patients

The analyzed articles provided data on 7297 patients with MIS-C associated with SARS-CoV-2 infection. The included studies collected data from the USA, Turkey, the UK, India, Brazil, Spain, Saudi Arabia, France, Colombia, Israel, Chile, Argentina, and Iran. The United States conducted the most significant number of studies on MIS-C, accounting for 33.3% of the cases. The age range of the children varied from 0 to 21 years, with a median age of 8.6 years. Among the patients in 19 studies, infants aged 0 - 10 months were included. All studies described the gender distribution among the affected children, revealing a total of 4329 male cases (59.2%). Regarding race and/or ethnicity, information on the incidence of MIS-C patients was reported in only 24 (53.3%) of the studies. Among the reported cases, there were 1413 (31.85%) individuals of Hispanic ethnicity and 2127 (50.82%) individuals of non-Hispanic ethnicity. Additionally, there were 1498 (26.84%) individuals of White ethnicity, 1548 (27.74%) individuals of Black ethnicity, 268 (4.8%) individuals of Asian ethnicity, and 180 (3.22%) individuals belonging to other ethnicities (Table 1).

Among the patients included in the analysis, 418 (14.8%) individuals reported contact with a confirmed SARS-CoV-2 infection case. Of the patients analyzed, 960 (34.4%) tested positive for SARS-CoV-2 through RT-PCR tests, while 1393 (49.3%) individuals had positive SARS-CoV-2 serology tests. Moreover, 228 (8%) patients demonstrated positive results for both RT-PCR and serology tests, indicating dual confirmation of SARS-CoV-2 infection.

Table 2 illustrates the presenting features reported in all but one study. The predominant presenting symptom was fever, followed by rash, conjunctivitis, and vomiting.

A comprehensive analysis was conducted on children, revealing the presence of various comorbidities in 2441 (33.3%) cases. Among the patients for whom data were available, obesity (27.13%) emerged as the predominant comorbidity. Additionally, several other comorbid conditions were identified but were less prevalent, affecting less than 10% of the patients. These less frequent comorbidities included chronic respiratory disease (6.47%), neurological disorders (2.01%), autoimmune diseases (0.98%), diabetes (0.46%),

hematologic disease (0.43%), eczema (0.04%), kidney disorders (0.04%), mitochondrial disorder, and chromosomal abnormalities (0.01%).

Thirty-four studies reported on cardiac involvement (6505 patients). Echocardiograms were performed in 6230 cases (95.77%). Of those with echocardiograms, 4829 patients (77.51%) were found to have abnormal results. The most prevalent abnormality observed was coronary artery dilatation or aneurysm, accounting for 893 cases (18.49%), followed by arrhythmia in 660 cases (13.66%). ECG outcomes were reported in only 6 out of 46 studies (n = 140, 35.53%). The predominant ECG changes noted were ST-segment elevation (46.42%), prolonged PR interval (14.28%), and bundle-branch block (11.42%).

#### 4.3. Laboratory Evaluation

The laboratory tests revealed abnormal levels of inflammatory, hematologic, and cardiac markers in the studies, with the details presented in Table 3.

#### 4.4. Therapeutic Management

Regarding the management of MIS-C, therapeutic approaches and supportive care were described in most studies. The mainstay of management for the MIS-C group included intravenous immunoglobulin (IVIG), steroids, and supportive therapy. Intravenous immunoglobulin therapy emerged as the most commonly used medication, administered in 4588 cases (80.73%), followed by steroids in 3730 cases (65.63%) across the majority of studies. Anticoagulation (enoxaparin or heparin) was administered to 883 patients (15.67%), while Aspirin, as antiplatelet therapy, was prescribed to 1073 patients (19.4%). A smaller proportion of patients, approximately 4.5% (n = 250), received other immunomodulators such as Anakinra, Tocilizumab, and Infliximab. Broad-spectrum antibiotics were used in the initial days of hospitalization to address possible sepsis, reported in 916 cases (16.26%). One hundred two patients required vasoactive drugs, and 496 patients (8.8%) needed inotropes for effective management of their condition. Among them, 374 patients (6.6%) required critical care, including intubation or invasive mechanical ventilation. Sixteen patients required extracorporeal membrane oxygenation (ECMO). Convalescent plasma therapy was the least commonly utilized approach, reported in only 12 patients (Table 4).

**Table 2.** Main Clinical Symptoms Extracted from Selected Studies

Main Clinical Symptoms	Patients with the Symptom/Patients with Available Data	Percent
<b>Constitutional</b>		
fever	1845/1869	98.71
<b>Gastrointestinal</b>		
Vomiting	3730/5348	50.89
Diarrhea	1465/2691	19.98
Abdominal pain	1769/2867	24.13
<b>Respiratory</b>		
Cough	1380/4776	28.89
Shortness of breath	426/1847	23.06
Severe respiratory involvement	162/2818	5.74
Pneumonia	781/2936	26.6
Sore throat	137/604	22.68
<b>Neurologic</b>		
Headache	207/752	27.52
Confusion	58/660	8.78
Seizure	17/539	3.15
Meningitis	123/2898	4.24
Encephalopathy	76/2818	2.69
Stroke	22/2818	0.78
<b>Mucocutaneous</b>		
Conjunctivitis	3013/5706	52.8
Rash	3113/5636	55.23
Dry cracked lips	219/526	41.63
Edema hand/feet	191/604	31.62
Oral mucosal changes	235/669	35.12
<b>Cardiovascular</b>		
Hypotension	332/4829	6.87
Arrhythmia	660/4829	13.66
Coronary artery dilatation/aneurysm	893/4829	18.49
Myocarditis	477/4829	9.87
Myocardial dysfunction	126/4829	2.6
Ventricular dysfunction	279/4829	5.7
Pericardial effusion	441/4829	9.13
Valvular insufficiency	115/4829	2.38
<b>Renal</b>		
Acute kidney injury	703/3570	19.69
Renal failure	186/3156	5.89
Shock	2316/5231	44.27
KD-like presentation	208/806	25.8

#### 4.5. Outcomes

All patients with MIS-C were hospitalized. Out of the total 7313 patients, 3784 (51.74%) required admission to the pediatric intensive care unit (PICU), with a median duration of 4.7 days (2 - 18 days). Among MIS-C cases, 127 deaths were reported, accounting for 1.7% of the total

patients. However, it is crucial to note that not all fatalities were directly attributed to MIS-C ([Table 4](#)).

#### 5. Discussion

Multisystem inflammatory syndrome in children is a consequence of an amplified innate and adaptive immune response, characterized by a pronounced cytokine storm. This heightened immune reaction is

**Table 3.** Laboratory Findings Extracted from Selected Studies

Laboratory Parameters	Patients with Abnormal Level/Patients with Available Data	Percent
<b>Inflammatory markers</b>		
↑ CRP	3042/3849	79.03
↑ ESR	795/1144	69.49
↑ Procalcitonin (ng/mL)	714/1218	58.62
↑ LDH	659/1148	57.40
↑ Fibrinogen	1195/2135	55.97
↑ D-dimer	2358/3329	71.64
↑ Ferritin	2788/2794	99.78
↑ IL-6	541/2196	24.63
↓ Albumin	909/1414	64.28
<b>Hematologic markers</b>		
↑ Neutrophil	524/641	81.74
↓ Lymphocyte (%)	2234/5179	43.13
↑ Leucocyte	539/1014	53.15
↓ platelets	2651/6100	43.45
<b>Cardiac biomarkers</b>		
Troponin	3120/5278	59.11
BNP	844/2377	35.5
proBNP	2254/5986	37.65

<sup>2</sup> Abbreviations: CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; LDH, lactate dehydrogenase; IL-6, interleukin 6; BNP, B-type natriuretic peptide.

presumed to be activated in susceptible children following prior exposure to SARS-CoV-2. The manifestation of MIS-C thus reflects the intricate interplay between the immune system and the viral pathogen, contributing to a more nuanced understanding of the syndrome's pathophysiology (55). This systematic review analyzed and summarized 44 published studies involving 7297 patients with MIS-C. While specific case definitions vary, definitions for MIS-C have been proposed by the CDC (56), the World Health Organization (WHO) (57), and the Royal College of Pediatrics and Child Health (RCPCH) (58).

Most of the included studies (32 studies) used the CDC clinical definition for MIS-C, while 12 adopted the WHO definition (six of which incorporated both CDC and WHO criteria). Additionally, seven studies employed the RCPCH definition (four using either CDC or RCPCH criteria), and two did not specify the criteria used. MIS-C can affect children at any age, ranging from infancy (<1 year) through late adolescence. The exact pathophysiology of the disease remains elusive due to the lack of precise data. Children with COVID-19 often display milder symptoms and are less frequently tested than adults.

Clinical laboratory testing has played a crucial role in managing SARS-CoV-2. While PCR-based assays have proven robust for virus detection, serology tests are also valuable as a complementary approach. In this review, all studies except for five (12, 32, 34, 35, 42) reported results of SARS-CoV-2 RT-PCR or serology tests.

In numerous systematic reviews of MIS-C, elevated levels of inflammatory markers such as CRP, ESR, procalcitonin, LDH, fibrinogen, D-dimer, ferritin, and IL-6 have been observed. This finding aligns with the results of several studies included in our research (59, 60). The precise factors driving this inflammatory response remain unclear, but it appears that infection with the virus triggers an immune system reaction.

It is crucial to acknowledge that COVID-19 tends to be more severe in patients with underlying medical conditions (61). In our review, the majority of children diagnosed with MIS-C had no pre-existing medical conditions, with obesity being the most frequently observed underlying condition (27.40%). Some studies have reported comorbidities with a frequency ranging between 20% and 25%. Apart from obesity (28, 52), other comorbidities were infrequent, primarily comprising respiratory diseases such as asthma and chronic lung disease, cardiovascular diseases, and

immunodeficiencies (4, 20, 28, 44). In a systematic review conducted by Kaushik et al., it was revealed that 23.3% of children exhibited comorbidities (43).

The findings in the current review confirm the diverse range of clinical manifestations, from mild to severe involvement. Fever was the most frequent symptom, followed by rash, vomiting, and conjunctivitis. In most reports, fever and gastrointestinal symptoms such as abdominal pain, diarrhea, and vomiting are described as the most common (60, 62). This contrasts with adults with COVID-19, where respiratory symptoms predominate (63). A significant portion of children in this review either did not exhibit respiratory symptoms (70%) (14, 20, 24, 28, 36, 41, 44, 47, 50, 52) or presented with milder manifestations.

Cardiac manifestations stand out as predominant symptoms in children with MIS-C. In suspected MIS-C patients, a complete cardiac evaluation should be conducted, including assessment of troponin and BNP levels, ECG, and echocardiogram. According to the findings of published studies, cardiac involvement is frequently detected in 67 – 80% of children across a spectrum of severity (34, 64). Based on our review, coronary artery dilatation or aneurysm was observed in 18.49% of cases, followed by arrhythmia in 13.66% of cases and ventricular dysfunction in 5.7% of cases. Notably, the frequency of ventricular dysfunction (34, 37, 49) and arrhythmias (22, 62, 65) in patients with MIS-C was lower than reported in several other studies (66, 67). During our review, we observed significant abnormalities in cardiac markers, including troponin, BNP, and proBNP.

Regarding cardiac involvement, 34 studies involving 4,829 patients were analyzed. Among these, 208 patients from 15 studies met the KD criteria (12, 14, 17, 18, 20, 22, 23, 25, 27, 29-31, 36, 42). Although MIS-C and Kawasaki disease share similar symptoms and characteristics, various reports have highlighted significant differences, such as age, that distinguish the two conditions (57, 68). Studies have shown that MIS-C typically affects older children, whereas KD has been reported in younger children under five (69-72). In our systematic review, the median age of patients with MIS-C was 8.6 years. Age (> 5 years) represents a significant risk factor associated with more severe outcomes in MIS-C (61, 73, 74).

In their study, Kaushik et al. documented cardiac involvement in MIS-C patients exhibiting a Kawasaki-like syndrome, with 20% displaying coronary artery

dilatation/aneurysms and hypotension, and 28% experiencing shock (75). In a variable proportion of MIS-C patients, hypotension and shock develop due to acute myocardial dysfunction. Our review found that hypotension occurred less frequently (4, 12, 16, 23, 25, 27, 30, 44, 51), but the incidence of shock (4, 13, 15-17, 19, 20, 22, 23, 26, 27, 29, 32, 37-39, 42, 45, 48) was comparable to other reviews (76-78).

Multisystem inflammatory syndrome in children patients are treated with various regimens. It should be noted that the primary treatment goals for MIS-C involve controlling systemic inflammation, supporting organ function, and reducing the risk of long-term complications (79). Intravenous immunoglobulin and/or steroids are the recommended initial treatment options for diagnosed MIS-C patients (37). While specific studies have indicated the benefits of combination therapy, there are currently no controlled trials directly comparing the efficacy of IVIG and corticosteroids administered alone or in combination. A study of 111 MIS-C patients found a lower treatment failure rate in those who received combination therapy compared to IVIG monotherapy (80). Similarly, another study focusing on MIS-C patients reported that initial treatment with IVIG and steroids was associated with a reduced risk of cardiovascular dysfunction (81). In our review, similar to previous reports, nearly all MIS-C patients received IVIG, with some also receiving combination therapy with steroids (27, 28, 40).

Less than 20% (18.08%) of patients received other immunomodulators, such as anakinra, tocilizumab, and infliximab. Aspirin and anticoagulants are commonly used medications in MIS-C. Given the potential overlap of MIS-C with severe bacterial infection, an initial approach involving empiric broad-spectrum antibiotics should be considered (82). However, it is essential to acknowledge that this approach may only be appropriate for certain patients (83). Recent studies suggest that antiviral therapy may reduce disease severity in some patients (84).

During our review, a significant proportion of MIS-C patients, comprising more than half of the cases, required admission to the PICU. Among those admitted, 53.9% exhibited shock symptoms, with 6.76% requiring intubation or invasive mechanical ventilation, 3.1% requiring non-invasive mechanical ventilation, and 3.7% succumbing during their PICU stay. Multisystem inflammatory syndrome in children emerged as the



primary reason for PICU admission associated with COVID-19 infection in Spain. Barrio's study noted that most patients presented with shock necessitating vasoactive drugs, with only a minority requiring ventilation (85).

Overall, in our review, the majority of patients studied experienced favorable outcomes, and all but 127 were discharged home in stable conditions. However, limited reports provided post-hospital discharge follow-up data. Mortality was lower compared to similar studies, such as the Colombian MISCO study (1.7% vs. 9%) (39). Variability in mortality rates among countries and studies may stem from several factors, including disparities in healthcare access and delays in early diagnosis. De Farias et al. identified a high prevalence of preexisting medical conditions and immunosuppression, which could contribute to the elevated mortality observed in MIS-C (26).

While our systematic review aimed to synthesize data on the epidemiological characteristics of MIS-C patients, providing accurate statistics on the incidence of MIS-C across different racial and ethnic groups was limited by the heterogeneity and incomplete reporting of race/ethnicity data in the included studies. However, investigations in some original studies suggest that race and ethnicity may influence the risk and burden of MIS-C. For example, Javalkar et al. found that Hispanic ethnicity and Black race independently increased the risk of MIS-C, even after accounting for socioeconomic factors (86). Similarly, Stierman et al. reported a higher frequency of MIS-C among Hispanic and non-Hispanic black children compared to the general pediatric population, while non-Hispanic White and non-Hispanic Asian children exhibited a lower frequency (87). These findings underscore the potential impact of race and ethnicity on MIS-C susceptibility and manifestation, potentially driven by genetic, socioeconomic, or environmental factors. Further research with standardized data collection and larger cohorts is necessary to clarify the extent of these disparities and their underlying mechanisms.

This systematic review comprehensively summarized the clinical features, management, and outcomes of patients with MIS-C across 44 global studies. Our search process was conducted meticulously, though we acknowledge the possibility of unintentionally overlooking certain studies. To maintain the integrity of our findings, we excluded studies or patients with

insufficient data or inadequate descriptions of MIS-C presentations. Specifically, our review did not include case reports, case series, or letters to the editor lacking detailed descriptions of pediatric MIS-C.

However, our study had some limitations worth noting. Firstly, our ability to gather sufficient data for robust analysis was hindered by the retrospective nature of some included studies and incomplete reporting of all variables. Consequently, formal statistical testing could not be conducted in this systematic review. Secondly, the absence of mean and standard deviation (SD) in certain studies limited our ability to directly perform meta-analysis, as we only had access to median, interquartile range (IQR), or range values. A third limitation was the exclusion of studies with sample sizes of fewer than 10 patients. Despite the substantial number of published MIS-C studies, we aimed to synthesize data from sufficiently large cohorts to draw generalizable conclusions. However, this exclusion criterion may have overlooked valuable data from smaller case series, potentially limiting the comprehensive capture of rare manifestations. While this approach aimed to enhance data accuracy by minimizing false positives, it might have unintentionally discounted critical clinical findings described solely in smaller studies. The significant heterogeneity among published MIS-C studies posed challenges for analysis, necessitating exclusions to effectively synthesize current literature. Future reviews could explore these smaller studies to extract additional details on atypical presentations indicative of severe disease courses. Finally, the novelty of MIS-C as a disease has resulted in a scarcity of post-discharge outcome studies, limiting our ability to thoroughly explore the underlying mechanisms of MIS-C.

## 6. Conclusions

Despite its limitations, this systematic review, involving 7,297 patients, provides crucial insights into the diverse clinical manifestations of MIS-C, underscoring the importance of prompt recognition and comprehensive evaluation. Intravenous immunoglobulin and corticosteroids emerged as mainstay therapies, yet evidence-based guidelines for optimal treatment combinations are needed. Vigilant monitoring and multidisciplinary care, including critical care support, are crucial, given that many patients required intensive care. While short-term

outcomes were favorable, the long-term implications remain unknown, highlighting the necessity for ongoing follow-up and surveillance studies.

## Footnotes

**Authors' Contribution:** Study concept and design, Asieh Mosallanejad; providing search strategy and retrieving the articles, Vahide Zeinali; screening and data extraction, Sharareh Kamfar, Asieh Mosallanejad, Fariba Alaei, Nazanin Farahbakhsh, and Shahrzad Tabatabaee; manuscript preparation, Sharareh Kamfar, Vahide Zeinali; critical revision, Asieh Mosallanejad, Fariba Alaei, Nazanin Farahbakhsh, and Shahrzad Tabatabaee.

**Conflict of Interests Statement:** The authors declare no conflicts of interest.

**Data Availability:** The data supporting this study's findings are available on request from the corresponding author.

**Funding/Support:** This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

## References

- Rafferty MS, Burrows H, Joseph JP, Leveille J, Nihtianova S, Amirian ES. Multisystem inflammatory syndrome in children (MIS-C) and the coronavirus pandemic: Current knowledge and implications for public health. *J Infect Public Health*. 2021;**14**(4):484-94. [PubMed ID: 33743370]. [PubMed Central ID: PMC7813487]. <https://doi.org/10.1016/j.jiph.2021.01.008>.
- Kurz H, Gombala T. Multisystem Inflammatory Syndrome in Children (MIS-C)-A Case Series in December 2020 in Vienna, Austria. *Front Pediatr*. 2021;**9**:656768. [PubMed ID: 34178882]. [PubMed Central ID: PMC8222512]. <https://doi.org/10.3389/fped.2021.656768>.
- Farooq A, Alam F, Saeed A, Butt F, Khaliq MA, Malik A, et al. Multisystem Inflammatory Syndrome in Children and Adolescents (MIS-C) under the Setting of COVID-19: A Review of Clinical Presentation, Workup and Management. *Infect Dis (Auckl)*. 2021;**14**:11786337211026600. [PubMed ID: 34220204]. [PubMed Central ID: PMC8221672]. <https://doi.org/10.1177/11786337211026642>.
- Dufort EM, Koumans EH, Chow EJ, Rosenthal EM, Muse A, Rowlands J, et al. Multisystem Inflammatory Syndrome in Children in New York State. *N Engl J Med*. 2020;**383**(4):347-58. [PubMed ID: 32598830]. [PubMed Central ID: PMC7346766]. <https://doi.org/10.1056/NEJMoa2021756>.
- Consiglio CR, Cotugno N, Sardh F, Pou C, Amodio D, Rodriguez L, et al. The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19. *Cell*. 2020;**183**(4):968-981 e7. [PubMed ID: 32966765]. [PubMed Central ID: PMC7474869]. <https://doi.org/10.1016/j.cell.2020.09.016>.
- Mansour Ghanaie R, Karimi A, Pourmoghaddas Z, Armin S, Fahimzad SA, Fallah F, et al. An Algorithmic Approach to Management of COVID-19 Associated Multisystem Inflammatory Syndrome in Children. *Arch Pediatr Infect Dis*. 2021;**9**(1). <https://doi.org/10.5812/pedinflect.110479>.
- Cdc Covid- Response Team. Coronavirus Disease 2019 in Children - United States, February 12-April 2, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;**69**(14):422-6. [PubMed ID: 32271728]. [PubMed Central ID: PMC7147903]. <https://doi.org/10.15585/mmwr.mm6914e4>.
- Sancho-Shimizu V, Brodin P, Cobat A, Biggs CM, Toubiana J, Lucas CL, et al. SARS-CoV-2-related MIS-C: A key to the viral and genetic causes of Kawasaki disease? *J Exp Med*. 2021;**218**(6). [PubMed ID: 33904890]. [PubMed Central ID: PMC8080850]. <https://doi.org/10.1084/jem.20210446>.
- Molloy EJ, Nakra N, Gale C, Dimitriades VR, Lakshminrusimha S. Multisystem inflammatory syndrome in children (MIS-C) and neonates (MIS-N) associated with COVID-19: optimizing definition and management. *Pediatr Res*. 2023;**93**(6):1499-508. [PubMed ID: 36050390]. [PubMed Central ID: PMC9436161]. <https://doi.org/10.1038/s41390-022-02263-w>.
- Sarkis-Onofre R, Catala-Lopez F, Aromataris E, Lockwood C. How to properly use the PRISMA Statement. *Syst Rev*. 2021;**10**(1):117. [PubMed ID: 33875004]. [PubMed Central ID: PMC8056687]. <https://doi.org/10.1186/s13643-021-01671-z>.
- Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. *The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses*. Ottawa, Canada: The Ottawa Hospital Research Institute; 2000, [cited 2023]. Available from: [https://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp).
- Abdel-Haq N, Asmar BI, Deza Leon MP, McGrath EJ, Arora HS, Cashen K, et al. SARS-CoV-2-associated multisystem inflammatory syndrome in children: clinical manifestations and the role of infliximab treatment. *Eur J Pediatr*. 2021;**180**(5):1581-91. [PubMed ID: 33452570]. [PubMed Central ID: PMC7810600]. <https://doi.org/10.1007/s00431-021-03935-1>.
- Alkan G, Sert A, Oz SKT, Emiroglu M, Yilmaz R. Clinical features and outcome of MIS-C patients: an experience from Central Anatolia. *Clin Rheumatol*. 2021;**40**(10):4179-89. [PubMed ID: 33956250]. [PubMed Central ID: PMC8100744]. <https://doi.org/10.1007/s10067-021-05754-z>.
- Basar EZ, Sonmez HE, Oncel S, Yetimakman AF, Babaoglu K. Multisystemic inflammatory syndrome in children associated with COVID-19: a single center experience in Turkey. *Turk Arch Pediatr*. 2021;**56**(3):192-9. [PubMed ID: 34104908]. [PubMed Central ID: PMC8152650]. <https://doi.org/10.5152/TurkArchPediatr.2021.21018>.
- Belhadjer Z, Meot M, Bajolle F, Khraiche D, Legendre A, Abakka S, et al. Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic. *Circul*. 2020;**142**(5):429-36. [PubMed ID: 32418446]. <https://doi.org/10.1161/CIRCULATIONAHA.120.048360>.
- Blumfield E, Levin TL, Kurian J, Lee EY, Liszewski MC. Imaging Findings in Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19). *AJR Am J Roentgenol*. 2021;**216**(2):507-17. [PubMed ID: 32755212]. <https://doi.org/10.2214/AJR.20.24032>.
- Capone CA, Subramony A, Sweberg T, Schneider J, Shah S, Rubin L, et al. Characteristics, Cardiac Involvement, and Outcomes of Multisystem Inflammatory Syndrome of Childhood Associated with severe acute respiratory syndrome coronavirus 2 Infection. *J Pediatr*.

- 2020;**224**:141-5. [PubMed ID: [32553873](#)]. [PubMed Central ID: [PMC7293762](#)]. <https://doi.org/10.1016/j.jpeds.2020.06.044>.
18. Carter MJ, Fish M, Jennings A, Doores KJ, Wellman P, Seow J, et al. Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. *Nat Med*. 2020;**26**(11):1701-7. [PubMed ID: [32812012](#)]. <https://doi.org/10.1038/s41591-020-1054-6>.
  19. Miller J, Cantor A, Zachariah P, Ahn D, Martinez M, Margolis KG. Gastrointestinal Symptoms as a Major Presentation Component of a Novel Multisystem Inflammatory Syndrome in Children That Is Related to Coronavirus Disease 2019: A Single Center Experience of 44 Cases. *Gastroenterol*. 2020;**159**(4):1571-1574 e2. [PubMed ID: [32505742](#)]. [PubMed Central ID: [PMC7270806](#)]. <https://doi.org/10.1053/j.gastro.2020.05.079>.
  20. Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P, et al. Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. *JAMA*. 2020;**324**(3):259-69. [PubMed ID: [32511692](#)]. [PubMed Central ID: [PMC7281356](#)]. <https://doi.org/10.1001/jama.2020.10369>.
  21. Davies P, Evans C, Kanthimathinathan HK, Lillie J, Brierley J, Waters G, et al. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. *Lancet Child Adolesc Health*. 2020;**4**(9):669-77. [PubMed ID: [32653054](#)]. [PubMed Central ID: [PMC7347350](#)]. [https://doi.org/10.1016/S2352-4642\(20\)30215-7](https://doi.org/10.1016/S2352-4642(20)30215-7).
  22. Dionne A, Mah DY, Son MBF, Lee PY, Henderson L, Baker AL, et al. Atrioventricular Block in Children With Multisystem Inflammatory Syndrome. *Pediatr*. 2020;**146**(5). [PubMed ID: [32855347](#)]. <https://doi.org/10.1542/peds.2020-009704>.
  23. Pouletty M, Borocco C, Ouldali N, Caseris M, Basmaci R, Lachaume N, et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort. *Ann Rheum Dis*. 2020;**79**(8):999-1006. [PubMed ID: [32527868](#)]. [PubMed Central ID: [PMC7299653](#)]. <https://doi.org/10.1136/annrheumdis-2020-217960>.
  24. Hameed S, Elbaaly H, Reid CEL, Santos RMF, Shivamurthy V, Wong J, et al. Spectrum of Imaging Findings at Chest Radiography, US, CT, and MRI in Multisystem Inflammatory Syndrome in Children Associated with COVID-19. *Radiol*. 2021;**298**(1):E1-E10. [PubMed ID: [32584166](#)]. [PubMed Central ID: [PMC7769068](#)]. <https://doi.org/10.1148/radiol.2020202543>.
  25. Dhanalakshmi K, Venkataraman A, Balasubramanian S, Madhusudan M, Amperayani S, Puttilibai S, et al. Epidemiological and Clinical Profile of Pediatric Inflammatory Multisystem Syndrome - Temporally Associated with SARS-CoV-2 (PIMS-TS) in Indian Children. *Indian Pediatr*. 2020;**57**(11):1010-4. [PubMed ID: [32769230](#)]. [PubMed Central ID: [PMC7678572](#)]. <https://doi.org/10.1007/s13312-020-2025-1>.
  26. de Farias ECF, Pedro Piva J, de Mello M, do Nascimento L, Costa CC, Machado MMM, et al. Multisystem Inflammatory Syndrome Associated With Coronavirus Disease in Children: A Multi-centered Study in Belem, Para, Brazil. *Pediatr Infect Dis J*. 2020;**39**(11):e374-6. [PubMed ID: [32826724](#)]. <https://doi.org/10.1097/INF.0000000000002865>.
  27. Moraleda C, Serna-Pascual M, Soriano-Arandes A, Simó S, Epalza C, Santos M, et al. Multi-inflammatory Syndrome in Children Related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Spain. *Clin Infect Dis*. 2021;**72**(9):e397-401. [PubMed ID: [32710613](#)]. [PubMed Central ID: [PMC7454331](#)]. <https://doi.org/10.1093/cid/ciaa1042>.
  28. Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. *N Engl J Med*. 2020;**383**(4):334-46. [PubMed ID: [32598831](#)]. [PubMed Central ID: [PMC7346765](#)]. <https://doi.org/10.1056/NEJMoa2021680>.
  29. Toubiana J, Poirault C, Corsia A, Bajolle F, Fourgeaud J, Angoulvant F, et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. *BMJ*. 2020;**369**:m2094. [PubMed ID: [32493739](#)]. [PubMed Central ID: [PMC7500538](#)]. <https://doi.org/10.1136/bmj.m2094>.
  30. Sozeri B, Caglayan S, Atasayan V, Ulu K, Coskuner T, Pelin Akbay O, et al. The clinical course and short-term health outcomes of multisystem inflammatory syndrome in children in the single pediatric rheumatology center. *Postgrad Med*. 2021;**133**(8):994-1000. [PubMed ID: [34605352](#)]. [PubMed Central ID: [PMC8544667](#)]. <https://doi.org/10.1080/00325481.2021.1987732>.
  31. Haslak F, Barut K, Durak C, Aliyeva A, Yildiz M, Guliyeva V, et al. Clinical features and outcomes of 76 patients with COVID-19-related multi-system inflammatory syndrome in children. *Clin Rheumatol*. 2021;**40**(10):4167-78. [PubMed ID: [34089099](#)]. [PubMed Central ID: [PMC8178032](#)]. <https://doi.org/10.1007/s10067-021-05780-x>.
  32. Bowen A, Miller AD, Zambrano LD, Wu MJ, Oster ME, Godfred-Cato S, et al. Demographic and Clinical Factors Associated With Death Among Persons Open Forum Infect Dis. 2021;**8**(8):ofab388. [PubMed ID: [34409123](#)]. [PubMed Central ID: [PMC8364981](#)]. <https://doi.org/10.1093/ofid/ofab388>.
  33. Al-Harbi S, Kazzaz YM, Uddin MS, Maghrabi F, Alnajjar AA, Muzaffer M, et al. Clinical characteristics and outcomes of multisystem inflammatory syndrome in children (MIS-C): a national multicenter cohort in Saudi Arabia. *Curr Pediatr Res*. 2021;**25**(9):904-13.
  34. Feldstein LR, Tenforde MW, Friedman KG, Newhams M, Rose EB, Dapul H, et al. Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19. *JAMA*. 2021;**325**(11):1074-87. [PubMed ID: [33625505](#)]. [PubMed Central ID: [PMC7905703](#)]. <https://doi.org/10.1001/jama.2021.2091>.
  35. Abrams JY, Oster ME, Godfred-Cato SE, Bryant B, Datta SD, Campbell AP, et al. Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA: a retrospective surveillance study. *Lancet Child Adolesc Health*. 2021;**5**(5):323-31. [PubMed ID: [33711293](#)]. [PubMed Central ID: [PMC7943393](#)]. [https://doi.org/10.1016/S2352-4642\(21\)00050-X](https://doi.org/10.1016/S2352-4642(21)00050-X).
  36. Acevedo L, Pineres-Olave BE, Nino-Serna LF, Vega LM, Gomez IJA, Chacon S, et al. Mortality and clinical characteristics of multisystem inflammatory syndrome in children (MIS-C) associated with covid-19 in critically ill patients: an observational multicenter study (MISCO study). *BMC Pediatr*. 2021;**21**(1):516. [PubMed ID: [34794410](#)]. [PubMed Central ID: [PMC8600488](#)]. <https://doi.org/10.1186/s12887-021-02974-9>.
  37. Valverde I, Singh Y, Sanchez-de-Toledo J, Theocharis P, Chikermane A, Di Filippo S, et al. Acute Cardiovascular Manifestations in 286 Children With Multisystem Inflammatory Syndrome Associated With COVID-19 Infection in Europe. *Circul*. 2021;**143**(1):21-32. [PubMed ID: [33166189](#)]. <https://doi.org/10.1161/CIRCULATIONAHA.120.050065>.
  38. Deep A, Upadhyay G, du Pre P, Lillie J, Pan D, Mudalige N, et al. Acute Kidney Injury in Pediatric Inflammatory Multisystem Syndrome Temporally Associated With Severe Acute Respiratory Syndrome

- Coronavirus-2 Pandemic: Experience From PICUs Across United Kingdom. *Crit Care Med*. 2020;**48**(12):1809-18. [PubMed ID: 33044282]. <https://doi.org/10.1097/CCM.0000000000004662>.
39. Tripathi S, Gist KM, Bjornstad EC, Kashyap R, Boman K, Chiotos K, et al. Coronavirus Disease 2019-Associated PICU Admissions: A Report From the Society of Critical Care Medicine Discovery Network Viral Infection and Respiratory Illness Universal Study Registry. *Pediatr Crit Care Med*. 2021;**22**(7):603-15. [PubMed ID: 33965987]. [PubMed Central ID: PMC8240492]. <https://doi.org/10.1097/PCC.0000000000002760>.
  40. Suresh Kumar A, Awasthi P, Thakur A, Randhawa MS, Nallasamy K, Kumar MR, et al. Intensive Care Needs and Short-Term Outcome of Multisystem Inflammatory Syndrome in Children (MIS-C): Experience From North India. *J Trop Pediatr*. 2021;**67**(3). [PubMed ID: 34170328]. [PubMed Central ID: PMC8344677]. <https://doi.org/10.1093/tropej/fmab055>.
  41. Martin B, DeWitt PE, Russell S, Anand A, Bradwell KR, Bremer C, et al. Children with SARS-CoV-2 in the National COVID Cohort Collaborative (N3C). *JAMA Network Open*. 2022;**5**(2). <https://doi.org/10.1101/2021.07.19.21260767>.
  42. Verdugo P, Alvarez P, Aroca P, Montes V, Poli C, Tapia L, et al. Hematologic parameters and biomarkers predictors of severity in Multisystem Inflammatory Syndrome in children associated with SARS-CoV-2. *Andes Pediatr*. 2021;**92**(3):382-8. [PubMed ID: 34479244]. <https://doi.org/10.32641/andespediatr.v92i3.3316>.
  43. Kaushik S, Aydin SI, Derespina KR, Bansal PB, Kowalsky S, Trachtman R, et al. Multisystem Inflammatory Syndrome in Children Associated with Severe Acute Respiratory Syndrome Coronavirus 2 Infection (MIS-C): A Multi-institutional Study from New York City. *J Pediatr*. 2020;**224**:24-9. [PubMed ID: 32553861]. [PubMed Central ID: PMC7293760]. <https://doi.org/10.1016/j.jpeds.2020.06.045>.
  44. Lee PY, Day-Lewis M, Henderson LA, Friedman KG, Lo J, Roberts JE, et al. Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children. *J Clin Invest*. 2020;**130**(11):5942-50. [PubMed ID: 32701511]. [PubMed Central ID: PMC7598077]. <https://doi.org/10.1172/JCI14113>.
  45. Lima-Setta F, Magalhaes-Barbosa MC, Rodrigues-Santos G, Figueiredo E, Jacques ML, Zeitel RS, et al. Multisystem inflammatory syndrome in children (MIS-C) during SARS-CoV-2 pandemic in Brazil: a multicenter, prospective cohort study. *J Pediatr (Rio J)*. 2021;**97**(3):354-61. [PubMed ID: 33186512]. [PubMed Central ID: PMC7649656]. <https://doi.org/10.1016/j.jpeds.2020.10.008>.
  46. Mamishi S, Movahedi Z, Mohammadi M, Ziaee V, Khodabandeh M, Abdolsalehi MR, et al. Multisystem inflammatory syndrome associated with SARS-CoV-2 infection in 45 children: a first report from Iran. *Epidemiol Infect*. 2020;**148**. e196. [PubMed ID: 32854812]. [PubMed Central ID: PMC7484297]. <https://doi.org/10.1017/S095026882000196X>.
  47. Nino-Taravilla C, Otaola-Arca H, Lara-Aguilera N, Zuleta-Morales Y, Ortiz-Fritz P. Multisystem Inflammatory Syndrome in Children, Chile, May-August 2020. *Emerg Infect Dis*. 2021;**27**(5):1457-61. [PubMed ID: 33760725]. [PubMed Central ID: PMC8084478]. <https://doi.org/10.3201/eid2705.204591>.
  48. Patnaik S, Jain MK, Ahmed S, Dash AK, P RK, Sahoo B, et al. Short-term outcomes in children recovered from multisystem inflammatory syndrome associated with SARS-CoV-2 infection. *Rheumatol Int*. 2021;**41**(11):1957-62. [PubMed ID: 34259880]. [PubMed Central ID: PMC8278175]. <https://doi.org/10.1007/s00296-021-04932-1>.
  49. Penner J, Abdel-Mannan O, Grant K, Maillard S, Kucera F, Hassell J, et al. 6-month multidisciplinary follow-up and outcomes of patients with paediatric inflammatory multisystem syndrome (PIMS-TS) at a UK tertiary paediatric hospital: a retrospective cohort study. *Lancet Child Adolesc Health*. 2021;**5**(7):473-82. [PubMed ID: 34043958]. [https://doi.org/10.1016/S2352-4642\(21\)00138-3](https://doi.org/10.1016/S2352-4642(21)00138-3).
  50. Ramcharan T, Nolan O, Lai CY, Prabhu N, Krishnamurthy R, Richter AG, et al. Paediatric Inflammatory Multisystem Syndrome: Temporally Associated with SARS-CoV-2 (PIMS-TS): Cardiac Features, Management and Short-Term Outcomes at a UK Tertiary Paediatric Hospital. *Pediatr Cardiol*. 2020;**41**(7):1391-401. [PubMed ID: 32529358]. [PubMed Central ID: PMC7289638]. <https://doi.org/10.1007/s00246-020-02391-2>.
  51. Roberts JE, Campbell JJ, Gauvreau K, Lamb GS, Newburger J, Son MB, et al. Differentiating multisystem inflammatory syndrome in children: a single-centre retrospective cohort study. *Arch Dis Child*. 2022;**107**(3). e3. [PubMed ID: 34244164]. [PubMed Central ID: PMC8275366]. <https://doi.org/10.1136/archdischild-2021-322290>.
  52. Swann OV, Holden KA, Turtle L, Pollock L, Fairfield CJ, Drake TM, et al. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. *Bmj*. 2020;**370**:m3249. [PubMed ID: 32960186]. [PubMed Central ID: PMC7488201]. <https://doi.org/10.1136/bmj.m3249>.
  53. Torres JP, Izquierdo G, Acuna M, Pavez D, Reyes F, Fritis A, et al. Multisystem inflammatory syndrome in children (MIS-C): Report of the clinical and epidemiological characteristics of cases in Santiago de Chile during the SARS-CoV-2 pandemic. *Int J Infect Dis*. 2020;**100**:75-81. [PubMed ID: 32861823]. [PubMed Central ID: PMC7452906]. <https://doi.org/10.1016/j.ijid.2020.08.062>.
  54. Rosanova MT, Perez G, Katsicas MM, Arias AP, Picollo M, Palladino M, et al. Pediatric Inflammatory Multisystem Syndrome Associated With SARS-CoV-2: A Retrospective Cohort Study From Argentina. *Indian Pediatr*. 2021;**58**(7):639-42. [PubMed ID: 33864452]. [PubMed Central ID: PMC8339158]. <https://doi.org/10.1007/s13312-021-2259-6>.
  55. Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID-19. *Nat Rev Rheumatol*. 2020;**16**(8):413-4. [PubMed ID: 32499548]. [PubMed Central ID: PMC7271827]. <https://doi.org/10.1038/s41584-020-0448-7>.
  56. MIS MIS. *Information for healthcare providers about Multisystem Inflammatory Syndrome in Children (MIS-C)*. Atlanta, Georgia: Centers for Disease Control and Prevention; 2020, [cited 2023]. Available from: [https://archive.cdc.gov/www\\_cdc\\_gov/mis/mis-c/hcp/index.html](https://archive.cdc.gov/www_cdc_gov/mis/mis-c/hcp/index.html).
  57. World Health Organization. *Multisystem inflammatory syndrome in children and adolescents with COVID-19*. Geneva, Switzerland: World Health Organization; 2020, [cited 2023]. Available from: <https://www.who.int/publications/i/item/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19>.
  58. Paediatrics R, Healthe C. *Guidance-Paediatric Multisystem Inflammatory syndrome Temporally Associated with COVID-19*. Theobald's Road, London: Royal College of Paediatrics and Child Health; 2020, [cited 2023]. Available from: <https://www.rcpch.ac.uk/sites/default/files/2020-05/COVID-19-Paediatric-multisystem-inflammatory-syndrome-20200501.pdf>.
  59. Guimarães D, Pissarra R, Reis-Melo A, Guimarães H. Multisystem inflammatory syndrome in children (MIS-C): A systematic review. *Int J Clin Practice*. 2021;**75**(11). <https://doi.org/10.1111/ijcp.14450>.
  60. Zhao Y, Yin L, Patel J, Tang L, Huang Y. The inflammatory markers of multisystem inflammatory syndrome in children (MIS-C) and adolescents associated with COVID-19: A meta-analysis. *J Med Virol*.

- 2021;**93**(7):4358-69. [PubMed ID: 33739452]. [PubMed Central ID: PMC8250955]. <https://doi.org/10.1002/jmv.26951>.
61. Rosenthal N, Cao Z, Gundrum J, Sianis J, Safo S. Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19. *JAMA Netw Open*. 2020;**3**(12): e2029058. [PubMed ID: 33301018]. [PubMed Central ID: PMC7729428]. <https://doi.org/10.1001/jamanetworkopen.2020.29058>.
  62. Haghghi Aski B, Manafi Anari A, Abolhasan Choobdar F, Zareh Mahmoudabadi R, Sakhaei M. Cardiac abnormalities due to multisystem inflammatory syndrome temporally associated with Covid-19 among children: A systematic review and meta-analysis. *Int J Cardiol Heart Vasc*. 2021;**33**:100764. [PubMed ID: 33778151]. [PubMed Central ID: PMC7983575]. <https://doi.org/10.1016/j.ijcha.2021.100764>.
  63. Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. *Lancet*. 2020;**395**(10239):1771-8. [PubMed ID: 32410760]. [PubMed Central ID: PMC7220177]. [https://doi.org/10.1016/S0140-6736\(20\)31103-X](https://doi.org/10.1016/S0140-6736(20)31103-X).
  64. Blondiaux E, Parisot P, Redheuil A, Tzaroukian L, Levy Y, Sileo C, et al. Cardiac MRI in Children with Multisystem Inflammatory Syndrome Associated with COVID-19. *Radiol*. 2020;**297**(3):E283-8. [PubMed ID: 32515676]. [PubMed Central ID: PMC7294821]. <https://doi.org/10.1148/radiol.2020202288>.
  65. Regan W, O'Byrne L, Stewart K, Miller O, Pushparajah K, Theocharis P, et al. Electrocardiographic Changes in Children with Multisystem Inflammation Associated with COVID-19: Associated with Coronavirus Disease 2019. *J Pediatr*. 2021;**234**:27-32 e2. [PubMed ID: 33358846]. [PubMed Central ID: PMC7836928]. <https://doi.org/10.1016/j.jpeds.2020.12.033>.
  66. Toubiana J, Levy C, Allali S, Jung C, Leruez-Ville M, Varon E, et al. Association between SARS-CoV-2 infection and Kawasaki-like multisystem inflammatory syndrome: a retrospective matched case-control study, Paris, France, April to May 2020. *Euro Surveill*. 2020;**25**(48). [PubMed ID: 33272357]. [PubMed Central ID: PMC7716402]. <https://doi.org/10.2807/1560-7917.ES.2020.25.48.2001813>.
  67. Alsaied T, Abouhosn JA, Cotts TB, Daniels CJ, Etheridge SP, Feltes TF, et al. Coronavirus Disease 2019 (COVID-19) Pandemic Implications in Pediatric and Adult Congenital Heart Disease. *J Am Heart Assoc*. 2020;**9**(12): e017224. [PubMed ID: 32441586]. [PubMed Central ID: PMC7429046]. <https://doi.org/10.1161/JAHA.120.017224>.
  68. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. *Lancet*. 2020;**395**(10237):1607-8. [PubMed ID: 32386565]. [PubMed Central ID: PMC7204765]. [https://doi.org/10.1016/S0140-6736\(20\)31094-1](https://doi.org/10.1016/S0140-6736(20)31094-1).
  69. Abrams JY, Godfred-Cato SE, Oster ME, Chow EJ, Koumans EH, Bryant B, et al. Multisystem Inflammatory Syndrome in Children Associated with Severe Acute Respiratory Syndrome Coronavirus 2: A Systematic Review. *J Pediatr*. 2020;**226**:45-54 e1. [PubMed ID: 32768466]. [PubMed Central ID: PMC7403869]. <https://doi.org/10.1016/j.jpeds.2020.08.003>.
  70. Ouldali N, Pouletty M, Mariani P, Beyler C, Blachier A, Bonacorsi S, et al. Emergence of Kawasaki disease related to SARS-CoV-2 infection in an epicentre of the French COVID-19 epidemic: a time-series analysis. *Lancet Child Adolesc Health*. 2020;**4**(9):662-8. [PubMed ID: 32622376]. [PubMed Central ID: PMC7332278]. [https://doi.org/10.1016/S2352-4642\(20\)30175-9](https://doi.org/10.1016/S2352-4642(20)30175-9).
  71. Abdel-Mannan O, Eyre M, Lobel U, Bamford A, Eltze C, Hameed B, et al. Neurologic and Radiographic Findings Associated With COVID-19 Infection in Children. *JAMA Neurol*. 2020;**77**(11):1440-5. [PubMed ID: 32609336]. [PubMed Central ID: PMC7330822]. <https://doi.org/10.1001/jamaneuro.2020.2687>.
  72. Chiotos K, Bassiri H, Behrens EM, Blatz AM, Chang J, Diorio C, et al. Multisystem Inflammatory Syndrome in Children During the Coronavirus 2019 Pandemic: A Case Series. *J Pediatric Infect Dis Soc*. 2020;**9**(3):393-8. [PubMed ID: 32463092]. [PubMed Central ID: PMC7313950]. <https://doi.org/10.1093/jpids/piaa069>.
  73. De Giorgi A, Fabbian F, Greco S, Di Simone E, De Giorgio R, Passaro A, et al. Prediction of in-hospital mortality of patients with SARS-CoV-2 infection by comorbidity indexes: an Italian internal medicine single center study. *Eur Rev Med Pharmacol Sci*. 2020;**24**(19):10258-66. [PubMed ID: 33090437]. [https://doi.org/10.26355/eurrev\\_202010\\_23250](https://doi.org/10.26355/eurrev_202010_23250).
  74. Dominguez-Ramirez L, Rodriguez-Perez F, Sosa-Jurado F, Santos-Lopez G, Cortes-Hernandez P. The role of metabolic comorbidity in COVID-19 mortality of middle-aged adults. The case of Mexico. *medRxiv*. 2020; **Perprint**:2020.12.15.20244160.
  75. Kaushik A, Gupta S, Sood M, Sharma S, Verma S. A Systematic Review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 Infection. *Pediatr Infect Dis J*. 2020;**39**(11):e340-6. [PubMed ID: 32925547]. <https://doi.org/10.1097/INF.0000000000002888>.
  76. Bustos B R, Jaramillo-Bustamante JC, Vasquez-Hoyos P, Cruces P, Diaz F. Pediatric Inflammatory Multisystem Syndrome Associated With SARS-CoV-2: A Case Series Quantitative Systematic Review. *Pediatr Emerg Care*. 2021;**37**(1):44-7. [PubMed ID: 33181794]. [PubMed Central ID: PMC7780931]. <https://doi.org/10.1097/PEC.0000000000002306>.
  77. Hoste L, Van Paemel R, Haerynck F. Multisystem inflammatory syndrome in children related to COVID-19: a systematic review. *Eur J Pediatr*. 2021;**180**(7):2019-34. [PubMed ID: 3359835]. [PubMed Central ID: PMC7890544]. <https://doi.org/10.1007/s00431-021-03993-5>.
  78. Zou H, Lu J, Liu J, Wong JH, Cheng S, Li Q, et al. Characteristics of pediatric multi-system inflammatory syndrome (PMIS) associated with COVID-19: a meta-analysis and insights into pathogenesis. *Int J Infect Dis*. 2021;**102**:319-26. [PubMed ID: 33202218]. [PubMed Central ID: PMC7666570]. <https://doi.org/10.1016/j.ijid.2020.11.145>.
  79. Nakra NA, Blumberg DA, Herrera-Guerra A, Lakshminrusimha S. Multi-System Inflammatory Syndrome in Children (MIS-C) Following SARS-CoV-2 Infection: Review of Clinical Presentation, Hypothetical Pathogenesis, and Proposed Management. *Children (Basel)*. 2020;**7**(7). [PubMed ID: 32630212]. [PubMed Central ID: PMC7401880]. <https://doi.org/10.3390/children7070069>.
  80. Ouldali N, Toubiana J, Antona D, Javouhey E, Madhi F, Lorrrot M, et al. Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children. *JAMA*. 2021;**325**(9):855-64. [PubMed ID: 33523115]. [PubMed Central ID: PMC7851757]. <https://doi.org/10.1001/jama.2021.0694>.
  81. Son MBF, Murray N, Friedman K, Young CC, Newhams MM, Feldstein LR, et al. Multisystem Inflammatory Syndrome in Children - Initial Therapy and Outcomes. *N Engl J Med*. 2021;**385**(1):23-34. [PubMed ID: 34133855]. [PubMed Central ID: PMC8220972]. <https://doi.org/10.1056/NEJMoa2102605>.
  82. Riollano-Cruz M, Akkoyun E, Briceno-Brito E, Kowalsky S, Reed J, Posada R, et al. Multisystem inflammatory syndrome in children related to COVID-19: A New York City experience. *J Med Virol*. 2021;**93**(1):424-33. [PubMed ID: 32584487]. [PubMed Central ID: PMC7361761]. <https://doi.org/10.1002/jmv.26224>.

83. Pereira MFB, Litvinov N, Farhat SCL, Eisencraft AP, Gibelli M, Carvalho WB, et al. Severe clinical spectrum with high mortality in pediatric patients with COVID-19 and multisystem inflammatory syndrome. *Clinics (Sao Paulo)*. 2020;**75**. e2209. [PubMed ID: 32844958]. [PubMed Central ID: PMC7426591]. <https://doi.org/10.6061/clinics/2020/e2209>.
84. Son MBF, Friedman K, Kaplan SL, Sundel R, Randolph AG. COVID-19: multisystem inflammatory syndrome in children (MIS-C) management and outcome. Up to Date; 2022, [cited 2023]. Available from: <https://medlib.ir/uptodate/show/129614>.
85. Slöcker Barrio M, García Salido A, Belda Höfheinz S, Guitart Pardellans C, De Carlos Vicente JC, Cuervas Mons Tejedor M, et al. PPO10 [Infections » Covid-19 / Sars-CoV-2]: Patients admitted to pediatric intensive care with sars-cov2: Results from a nationwide multicentre study. *Pediatric Critical Care Medicine*. 2022;**23**(Supplement 1 (11S)). <https://doi.org/10.1097/01.pcc.0000900020.76616.a3>.
86. Javalkar K, Robson VK, Gaffney L, Bohling AM, Arya P, Servattalab S, et al. Socioeconomic and Racial and/or Ethnic Disparities in Multisystem Inflammatory Syndrome. *Pediatr*. 2021;**147**(5). [PubMed ID: 33602802]. [PubMed Central ID: PMC8086000]. <https://doi.org/10.1542/peds.2020-039933>.
87. Stierman B, Abrams JY, Godfred-Cato SE, Oster ME, Meng L, Yip L, et al. Racial and Ethnic Disparities in Multisystem Inflammatory Syndrome in Children in the United States, March 2020 to February 2021. *Pediatr Infect Dis J*. 2021;**40**(11):e400-6. [PubMed ID: 34382615]. [PubMed Central ID: PMC8505134]. <https://doi.org/10.1097/INF.0000000000003294>.

**Table 4.** Therapeutic Management and Outcomes Extracted from Selected Studies

Study No	PICU Admission No.	Therapeutic Management	Outcomes	Mortality
1	22	IVIG (n = 29), steroids (n = 27), infliximab (n = 12), aspirin (n = 29), antibiotics (n = 27), antivirals (n = 27)	Mechanical ventilation (n = 9), inotropic support (n = 24), ECMO (n = 3)	0
2	4	IVIG (n = 36), methylprednisolone (n = 36), enoxaparin (n = 36), aspirin (n = 36), antibiotics (n = 26)	NR	8
3	2	IVIG (n = 11), methylprednisolone (n = 10), enoxaparin (n = 11), aspirin (n = 11), anti-interleukin-1 (n = 2)	Inotropic support (n = 3).	1
4	35	IVIG (n = 25), steroids (n = 12), anti-interleukin-1 (n = 3), heparin (n = 23),	Inotropic support (n = 28), non-invasive mechanical ventilation (n = 11), invasive mechanical ventilation (n = 22)	0
5	11	IVIG (n = 5), steroids (n = 10), anti-interleukin-1 (n = 2),	Intubation (n = 1),	0
6	26	IVIG (n = 33), methylprednisolone (n = 23), anti-interleukin-1 (n = 4), inhibitor of il-6r, tocilizumab (n = 3), infliximab (n = 1), enoxaparin (n = 14), aspirin (n = 29)	Mechanical ventilation (n = 6)	0
7	21	IVIG (n = 23), steroids (n = 20), biologic immunomodulation (n = 14)	Mechanical ventilation (n = 12).	0
8	NR	IVIG (n = 36), steroids (n = 42), anticoagulation (n = 40), anti-interleukin-1 (n = 8)	Intubation or invasive mechanical ventilation (n = 1), renal replacement therapy (n = 1)	0
9	29	IVIG (n = 41), steroids (n = 37), anti-interleukin-1 (n = 3), infliximab (n = 8)	Intubation or invasive mechanical ventilation (n = 25), inotropic support (n = 27), ECMO (n = 3)	1
10	78	IVIG (n = 59), steroids (n = 57), anti-interleukin-1 (n = 8), infliximab (n = 7), tocilizumab (n = 3), rituximab (n = 1), aspirin (n = 45), antibiotics (n = 78), antivirals (n = 1)	Intubation or invasive mechanical ventilation (n = 36), non-invasive mechanical ventilation (n = 5), inotropic support (n = 65), renal replacement therapy (n = 1)	2
11	79	IVIG (n=69), Steroids (n=63), Glucocorticoids and IVIG (n=48)	Vasopressor support (n=61), mechanical ventilation (n=10), ECMO (n=4)	2
12	14	IVIG (n = 16), steroids (n = 13), anti-interleukin-1 (n = 4), enoxaparin (n = 14), aspirin (n = 14), antivirals (n = 9)	Non-invasive mechanical ventilation (n = 6), inotropic support (n = 7)	0
13	118	IVIG (n = 189), steroids (n = 149), aspirin (n = 196), anti-interleukin-1 (n = 10), inhibitor of il-6r (n = 4), antibiotics (n = 249), antivirals (n = 18)	Non-invasive mechanical ventilation (n = 44), inotropic support (n = 80), dialysis (n = 1)	3
14	24	IVIG (n = 35), steroids (n = 35)	Mechanical ventilation (n = 35), inotropic support (n = 20), ECMO (n = 2)	1
15	12	IVIG (n = 15), steroids (n = 11), aspirin (n = 16), inhibitor of IL-6R (n = 1)	Vasoactive support (n = 6), fluid resuscitation (n = 10)	0
16	11	NR	Intubation or invasive mechanical ventilation (n=3), non-invasive mechanical ventilation (n=4), fluid resuscitation (n=8)	2
17	20	IVIG (n = 20), steroids (n = 21), both IVIG and corticosteroids (n = 13), antibiotics (n = 3), antivirals (n = 9)	Intubation or invasive mechanical ventilation (n = 6), fluid resuscitation (n = 2)	1
18	148	IVIG (n = 144), steroids (n = 91), anticoagulation (n = 14), interleukin-6 inhibitor (n = 14), interleukin-1r inhibitor (n = 24)	Intubation or invasive mechanical ventilation (n = 37), ECMO (n = 8)	4
19	17	IVIG (n = 21), steroids (n = 7), aspirin (n = 21), antibiotics (n = 18)	Mechanical ventilation (n = 11), inotropic support (n = 18)	0
20	21	IVIG (n = 58), steroids (n = 45), anti-interleukin-1 (n = 17), tocilizumab (n = 1), enoxaparin (n = 42)	Vasoactive medications (n = 14), mechanical ventilation (n = 2), ECMO (n = 2)	2
21	27	IVIG (n = 76), steroids (n = 74), anticoagulation (n = 70), anti-interleukin-1 (n = 3), antivirals (n = 7)	Intubation or invasive mechanical ventilation (n = 3), non-invasive mechanical ventilation (n = 9), inotropic support (n = 22), Plasmapheresis (n = 14)	1
22	1628	IVIG (n = 33), steroids (n = 14), both IVIG and glucocorticoids (n = 14)	NR	35
23	54	IVIG (n = 50), steroids (n = 47), anti-interleukin-1 (n = 17), tocilizumab (n = 8), aspirin (n = 27), enoxaparin (n = 16), macrolides (n = 26), hydroxychloroquine (n = 2), antivirals (n = 21), antibiotics (n = 53)	Mechanical ventilation (n=43), inotropic support (n=32)	9
24	NR	IVIG (n = 15), aspirin (n = 8), anti-interleukin-1 (n = 1), anti-il-6 treatment (n = 1), hydroxychloroquine (n = 1),	Intubation or invasive mechanical ventilation (n = 2), non-invasive mechanical ventilation (n = 3).	0
25	398	IVIG (n = 415), steroids (n = 374), anticoagulation (n = 337), aspirin (n = 308), tocilizumab (n = 32), hydroxychloroquine (n = 14)	Convalescent plasma therapy (n = 10)	10
26	684	NR	NR	18
27	78	IVIG (n = 71), steroids (n = 55), anticoagulation (n = 34), aspirin (n = 34), immunomodulator (eculizumab) (n = 1)	Vasoactive drugs (n = 59), respiratory support (n = 54), dialysis (n = 9)	7
28	NR	IVIG (n = 224), steroids (n = 80), anticoagulation (n = 108), aspirin (n = 212), diuretics (n = 175), antibiotics (n = 202), antivirals (n = 20).	Inotropic support (n = 80)	1
29	NR	NR	Intubation or invasive mechanical ventilation (n = 41), inotropic support (n = 74), vasoconstricted shock (n=), vasodilated shock (n = 57)	2
30	NR	IVIG (n = 78), steroids (n = 115), anticoagulation (n = 39), anti-interleukin-1 (n = 21), antibiotics (n = 13), hydroxychloroquine (n = 5), antivirals (n = 27)	Convalescent plasma therapy (n = 1), intubation or invasive mechanical ventilation (n = 30), non-invasive mechanical ventilation (n = 32), inotropic support (n = 73)	8

Study No	PICU Admission No.	Therapeutic Management	Outcomes	Mortality
			26)	2
32	NR	NR	Intubation or invasive mechanical ventilation (n = 12), inotropic support (n = 31)	0
33	24	IVIg (n = 24), steroids (n = 21), enoxaparin (n = 24), aspirin (n = 23), tocilizumab (n = 2), infliximab (n = 1)	NR	0
34	33	IVIg (n = 18), steroids (n = 17), tocilizumab (n = 7), anti-interleukin-1 (n = 4), anticoagulation (n = 32), antibiotics (n = 15), antiviral (n = 7)	Convalescent plasma therapy (n = 1), Vasoactive medications (n = 17), intubation or invasive mechanical ventilation (n = 5), non-invasive mechanical ventilation (n = 2), ECMO (n = 1)	1
35	17	IVIg (n = 22), anti-interleukin-1 (n = 5), steroids (n = 17)	Non-invasive mechanical ventilation (n = 7)	0
36	NR	IVIg (n = 50), steroids (n = 31), enoxaparin (n = 29), aspirin (n = 25), antibiotics (n = 33), antivirals (n = 5)	Intubation or invasive mechanical ventilation (n = 6), non-invasive mechanical ventilation (n = 3)	1
37	NR	IVIg (n = 18), steroids (n = 27)		5
38	NR	IVIg (n = 16), steroids (n = 18), tocilizumab (n = 3), infliximab (n = 1)	Vasoactive drugs (n = 13), intubation or invasive mechanical ventilation (n = 10).	0
39	10	IVIg (n = 7), steroids (n = 20), enoxaparin (n = 20),	Intubation or non-invasive mechanical ventilation (n = 5)	0
40	NR	IVIg (n = 38), steroids (n = 25), enoxaparin (n = 35), anti-interleukin-1 (n = 6),	Mechanical ventilation (n = 16), inotropic support (n = 22)	0
41	10	IVIg (n=10), Methylprednisolone (n=5), Aspirin (n=11), Antibiotics (n=15)	Intubation or invasive mechanical ventilation (n=10), non-invasive mechanical ventilation (n=4), respiratory support (n=4)	0
42	25	NR	Mechanical ventilation (n = 2), ECMO (n = 1)	0
43	38	IVIg (n = 28), steroids (n = 24), anti-interleukin-1 (n = 3), tocilizumab (n = 1), adalimumab (n = 1), infliximab (n = 1), antibiotics (n = 186), antivirals (n = 38).	Intubation or invasive mechanical ventilation (n = 14), non-invasive mechanical ventilation (n = 18), inotropic support (n = 25)	0
44	16	IVIg (n = 19), steroids (n = 17), enoxaparin (n = 18), aspirin (n = 17), antibiotics (n = 24),	Intubation or invasive mechanical ventilation (n = 12), oxygen (n = 13), vasoactive drugs (n = 12)	0

<sup>z</sup> Abbreviation: NR, Not Reported; IVIG, intravenous immunoglobulin.